CARMA FUND
CARMA FUND I is an early-stage investment fund for advancing Life Science and Healthcare technologies. The fund started off with a First Closing in June 2022 and has €56M under management. It is based in Munich and Frankfurt am Main. Starting to develop new products and services for the patients’ well-being and medical advancements comes with its unique challenges and opportunities. Biotech/healthcare is a specialist business and as such innovators have often struggled to rope in reliant streams of outside capital necessary for quick and effi cient development towards a market entry. The Fund was initiated by the two technology transfer companies Innovectis (Frankfurt) and Ascenion (Munich).
| Capital under management | CARMA has €56M under management. |
| Investment requirements and financing offer | CARMA FUND I is uniquely suited for young Eurpean companies and projects from the Life Science and medical space due to an extra-long term, fl exible investment modes and its relationships with leading technology transfer offi ces and industry partners. CARMA invests in pre-seed, seed, and series A. |
| Industry focus | CARMA FUND is investing in opportunities from the European Life Science and Healthcare sector. THERAPEUTICS MEDTECH DIAGNOSTICS DIGITAL HEALTH |
| Portfolio and exits | Acorai, Aignostics, Allogenetics, Akribion, Ceregate, Dimericon Therapeutics, Epignostix, Genome Biologics, Incontalert, Kupando, O11 Medical, Salvina, Symphera, Tecregen, Thryve, Elkedonia |
| Memberships in networks/associations | ASTP: This association is Europe’s association of knowledge transfer professionals with two decades of experience in educating, connecting and advocating for the profession. bioRN, the science and industry innovation cluster in the Rhine- Neckar region around Heidelberg |
Kontakt:
| Address | CARMA Fund Management GmbH Herzogstrasse 64 München 80803 |
| Telephone | +49 15153946465 |
| martin.raditsch@carma-fund.com | |
| Social Media | www.linkedin.com/in/martin-raditsch |
| Web Address | www.carma-fund.com |
| Date of foundation/ Number of employees |
June 2022/4 |
ARTIKEL ZU DIESEN SCHLAGWORTEN
- Qiagen überzeugt mit 2025er-Zahlen
- „Höhere Risiken gehen wir bei sogenannten Seismic-Shift-Wetten ein.“
- „Sie fallen durch alle klassischen Raster – und genau dort sehen wir unsere Rolle.“
- „Der zweite Fonds ist keine Neuausrichtung, sondern die Skalierung eines bewährten Modells.“
- JPM 2026: Von Modalitäten zu Umsetzung
- „Wir verbinden frühes Kapital, industriellen Zugang und Erfahrung.“
- GetYourGuide macht sich fit für die Börse
- Exciva: 51 Mio. EUR Serie B für Therapie Alzheimer-bedingter Unruhe
- "Deshalb planen wir eine zeitnahe Finanzierungsrunde."
- Biotech Basket mit gutem Schlussquartal
- 1,8 Mrd. für die deutsche Biotechnologie
- Leo International Precision Health AG
- Weihnachtsgeschenk für T-CURX: Series A mit 20 Mio. USD Ziel
- Tubulis: Kampf dem Krebs
- Zur EU-Bioökonomiestrategie: „Findings are not bindings“
- Biotechnologie 2025: Umbrüche und Neuerungen
- Kommerzialisierungs-Strategien für junge Biopharmazeutika-Entwickler
- Amplifold: 5 Mio. EUR für DNA-Origami-Schnelltests
- Case Study Varolis GmbH: Summen fürs Summen
- Wie recyclen wir uns aus der Rohstoffabhängigkeit?